FDA approved the third oncology drug in the US that targets a key genetic driver of cancer, rather than a specific tumor.
Products marketed as a numbing agent/topical anesthetic used prior to tattoo application.
CarePass program appeals to wide consumer audience, trial finds.
More jobs in jeopardy as chains struggle to save expenses.
50 new recommendations signed by organizations, schools, and regulators.
Update: ASHP statement released.
Survey indicates need for greater pharmacist presence.
FDA approved yet another indication for pembrolizumab (Keytruda) to treat patients with recurrent, locally advanced or metastatic, squamous cell carcinoma of the esophagus (ESCC).
Drug to treat prostate cancer is expected to produce a major windfall for two pharma makers.
How to handle controlled substances and medication safely.